Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLBS16 in Coronary Microvascular Dysfunction
NCT04614467Phase 2Terminated
- Sponsor
- Lisata Therapeutics
- Start
- Oct 2020
- Primary completion
- Sep 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Coronary Microvascular Dysfunction (CMD) comparing CLBS16 with Placebo (2 arms). Primary endpoints: Change From Baseline in Number of Angina Attacks Per Week at 3 months, Change From Baseline in CCS Angina Class at 3 months and 2 more. Started Oct 2020; status: terminated.
02
Drugs
autologous CD34+ cells
03
Conditions
Coronary Microvascular Dysfunction (CMD)
Beyond the preview
Go deeper on NCT04614467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04614467.